RheumaGen
DENVER, CO · Biotechnology · 6 employees
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado.
Funding history
- Series A — Undisclosed — Dec 2025
- Series A — $15.0M — Jan 2025
- Seed — $700K — Apr 2024
- Seed — $4.9M — Apr 2024
- Seed — $300K — May 2023
Recent signals
- Dec 22, 2025: Raised funding in Series A
- Jan 09, 2025: Raised $15.0M in Series A
- Apr 17, 2024: Raised $700K in Seed
- Apr 17, 2024: Raised $4.9M in Seed
- May 26, 2023: Raised $300K in Seed
See plans & pricing → Track RheumaGen’s funding, hiring, and signals — with verified contacts — on Fundz.